New study looks at FDA's use of so­cial me­dia to com­mu­ni­cate on drug safe­ty

A new study look­ing at the FDA use of so­cial me­dia to com­mu­ni­cate about drug safe­ty finds that the agency could im­prove its im­pact by de­vel­op­ing so­cial me­dia strate­gies and tak­ing a more ac­tive role on web plat­forms.

The study, con­duct­ed by re­searchers at Har­vard Med­ical School, North­east­ern Uni­ver­si­ty, Boston Chil­dren’s Hos­pi­tal and The Ohio State Uni­ver­si­ty, and fund­ed by FDA’s Cen­ter for Drug Eval­u­a­tion and Re­search, looks specif­i­cal­ly at FDA’s use of so­cial me­dia fol­low­ing two drug safe­ty com­mu­ni­ca­tions (DSCs) for drugs con­tain­ing zolpi­dem, the ac­tive in­gre­di­ent in Am­bi­en.

In 2013, FDA is­sued two DSCs re­lat­ed to zolpi­dem, the first in Jan­u­ary warn­ing of the risk of next-day im­pair­ment af­ter tak­ing in­som­nia drugs and re­quir­ing low­er rec­om­mend­ed dos­es for drugs con­tain­ing zolpi­dem, and the sec­ond no­ti­fy­ing the pub­lic that the agency had ap­proved those la­bel­ing changes.

In ad­di­tion to pub­lish­ing the DSCs to its web­site, FDA made posts re­lat­ed to the DSCs on its var­i­ous so­cial me­dia ac­counts, in­clud­ing its Face­book page and three of its Twit­ter ac­counts (@US_FDA@FDA_Drug_In­fo and @FDAMed­Watch).

For the first DSC, FDA post­ed once to its Face­book ac­count, get­ting 61 shares, and tweet­ed six times across its three ac­counts, for a to­tal of 111 retweets.

To mea­sure the im­pact of FDA’s posts, the au­thors iden­ti­fied some 174,000 tweets and 59,000 Face­book posts ref­er­enc­ing zolpi­dem be­tween 1 Oc­to­ber 2012 and 31 Au­gust 2013. Of those, rough­ly 9% of the tweets were tagged as ad­verse events (AEs), 74% were tagged as men­tions and 17% were con­sid­ered junk. For the Face­book posts, 5% were iden­ti­fied as AEs, 69% as men­tions and 26% as junk.

How­ev­er, for the sec­ond DSC, FDA did not post to Face­book and on­ly tweet­ed about the DSC for its@FDA_Drug_In­fo ac­count (3 tweets, 37 retweets), though the agency al­so tweet­ed gen­er­al­ly about a group of re­cent pre­scrib­ing changes, in­clud­ing for zolpi­dem, from its@FDAMed­Watch ac­count.

The au­thors ob­served a greater so­cial me­dia re­sponse from both Twit­ter and Face­book users fol­low­ing the first DSC, but did not no­tice an in­crease in so­cial ac­tiv­i­ty re­lat­ed to zolpi­dem fol­low­ing the sec­ond com­mu­ni­ca­tion.

The au­thors say that the dif­fer­ence in so­cial me­dia re­sponse to the two safe­ty com­mu­ni­ca­tions can be ex­plained by the dif­fer­ence in how FDA is­sued the com­mu­ni­ca­tions. In ad­di­tion to post­ing about the first DSC more fre­quent­ly and to more of its ac­counts, the first DSC was al­so is­sued with an ac­com­pa­ny­ing press re­lease.

Rec­om­men­da­tions

To make bet­ter use of its so­cial me­dia pres­ence in the fu­ture, the au­thors rec­om­mend that FDA de­vel­op strate­gies for how and how of­ten to post dif­fer­ent types of mes­sages.

“Since there can be a lot of ques­tion­able in­for­ma­tion shared on so­cial me­dia, the FDA should be able to lever­age its in­de­pen­dent ex­per­tise and po­si­tion as a wide­ly trust­ed source of in­for­ma­tion to help pro­mote ac­cu­rate and in­for­ma­tive mes­sages. In the case of the zolpi­dem safe­ty alerts, the FDA took some steps to do that, but could cre­ate more out­reach and dis­sem­i­nate its ma­te­ri­als more fre­quent­ly via var­ied plat­forms,” Michael Sin­ha, a post­doc­tor­al fel­low at Har­vard and lead au­thor on the pa­per told Fo­cus.

Sin­ha al­so em­pha­sized that the so­cial me­dia land­scape is sub­stan­tial­ly dif­fer­ent now than in 2013 when these safe­ty com­mu­ni­ca­tions were is­sued.

“So­cial me­dia like Twit­ter was seen as more of a recre­ation­al tool in 2013, but now many pro­fes­sion­als, aca­d­e­m­ic in­sti­tu­tions and com­pa­nies have vi­brant so­cial me­dia pres­ences. In­creased health pro­fes­sion­al en­gage­ment on so­cial me­dia in­creas­es the like­li­hood that FDA con­tent on these plat­forms would be more wide­ly dis­sem­i­nat­ed and have a greater im­pact,” he said.

The pa­per al­so rec­om­mends that FDA de­vel­op a greater un­der­stand­ing of so­cial me­dia plat­form fea­tures and user pref­er­ences to de­vel­op its ap­proach to post­ing.

“FDA should try to stay on top of the ever-evolv­ing strate­gies be­ing de­vel­oped on so­cial me­dia to am­pli­fy mes­sages—such as use of han­dles or hash­tags on Twit­ter—that can bring at­ten­tion to im­por­tant drug safe­ty con­tent dis­sem­i­nat­ed by the agency,” Sin­ha said.

The au­thors al­so sug­gest that FDA should take mat­ters in­to its own hands when it comes to up­dat­ing in­for­ma­tion about drugs on Wikipedia.

De­spite mul­ti­ple ed­its to the Wikipedia page cor­re­spond­ing to both com­mu­ni­ca­tions, the pages con­tained in­com­plete in­for­ma­tion and did not cite the DSCs them­selves.

“Giv­en that in­for­ma­tion­al sites like Wikipedia are com­mon­ly ac­cessed by the lay pub­lic for in­for­ma­tion on drugs and that any­one can ed­it the con­tent, the FDA should con­sid­er a plan to for­mal­ly up­date the pages for ap­pro­pri­ate con­tent at the time a DSC is re­leased and to en­sure con­tin­ued ac­cu­ra­cy of the in­for­ma­tion over time,” the au­thors write.


First pub­lished here. Reg­u­la­to­ry Fo­cus is the flag­ship on­line pub­li­ca­tion of the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety (RAPS), the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care and re­lat­ed prod­ucts, in­clud­ing med­ical de­vices, phar­ma­ceu­ti­cals, bi­o­log­ics and nu­tri­tion­al prod­ucts. Email news@raps.org for more in­for­ma­tion.

Scott Gottlieb, AP Images

Scott Got­tlieb is once again join­ing a team that en­joyed good times at the FDA un­der his high-en­er­gy stint at the helm

Right after jumping on Michael Milken’s FasterCures board on Monday, the newly departed FDA commissioner is back today with news about another life sciences board post that gives him a ringside chair to cheer on a lead player in the real-world evidence movement — one with very close ties to the FDA.

Aetion is reporting this morning that Gottlieb is joining their board, a group that includes Mohamad Makhzoumi, a general partner at New Enterprise Associates, where Gottlieb returned after stepping out of his role at the FDA 2 years after he started.

Gottlieb — one of the best connected execs in biopharma — knows this company well. As head of FDA he championed the use of real-world evidence to help guide drug developers and the agency in gaining greater efficiencies, which helped set up Aetion as a high-profile player in the game.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,600+ biopharma pros reading Endpoints daily — and it's free.

San Diego cou­ple charged with steal­ing trade se­crets, open­ing Chi­nese biotech as DOJ crack­down con­tin­ues

A San Diego couple has been charged with stealing trade secrets from a US hospital and opening a business based off those secrets in China as the controversial industry-wide crackdown on alleged corporate espionage continues. On the same day, the Department of Justice announced they had arrested Beijing representative Zhongsan Liu for allegedly trying to obtain research visas for government recruiters.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,600+ biopharma pros reading Endpoints daily — and it's free.

Deborah Dunsire. Lundbeck

UP­DAT­ED: Deb­o­rah Dun­sire is pay­ing $2B for a chance to leap di­rect­ly in­to a block­buster show­down with a few of the world's biggest phar­ma gi­ants

A year after taking the reins as CEO of Lundbeck, Deborah Dunsire is making a bold bid to beef up the Danish biotech’s portfolio of drugs in what will likely be a direct leap into an intense rivalry with a group of giants now carving up a growing market for new migraine drugs.

Bright and early European time Monday morning the company announced that it will pay up to about $2 billion to buy Alder, a little biotech that is far along the path in developing a quarterly IV formulation of a CGRP drug aimed at cutting back the number of crippling migraines patients experience each month. In a followup call, Dunsire also noted that the company will likely need 200 to 250 reps for this marketing task on both sides of the Atlantic. And analysts were quick to note that the dealmaking at Lundbeck isn’t done, with another $2 billion to $3 billion available for more deals to beef up the pipeline.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,600+ biopharma pros reading Endpoints daily — and it's free.

Tower Bridge in London [Shutterstock]

#UK­BIO19: Join GSK’s Hal Bar­ron and a group of top biotech ex­ecs for our 2nd an­nu­al biotech sum­mit in Lon­don

Over the past 10 years I’ve made a point of getting to know the Golden Triangle and the special role the UK biopharma industry plays there in drug development. The concentration of world class research institutes, some of the most accomplished scientists I’ve ever seen at work and a rising tide of global investment cash leaves an impression that there’s much, much more to come as biotech hubs are birthed and nurtured.

UP­DAT­ED: Bio­gen pulls the plug on prized IPF drug from $562M+ Stromedix buy­out

One of Biogen’s attempts to branch out has flopped as the biotech scraps a mid-stage program for idiopathic pulmonary fibrosis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,600+ biopharma pros reading Endpoints daily — and it's free.

Warts for the win: Aclar­is' lead drug clears piv­otal study

Aclaris Therapeutics has found a way to get rid of the warts and all.

The company — which earlier this month decided to focus on its arsenal of kinase inhibitors — on Monday unveiled positive data from a pivotal study testing its lead experimental drug for use in common warts.

The drug, A-101, was tested in a 502-patient study called THWART-2 — patients enrolled had one to six warts before qualifying for the trial. Patients either self-administered A-101 topical solution or a vehicle twice a week over a two-month period. A higher proportion of patients on the drug (a potent hydrogen peroxide topical solution) saw their warts disappear at day 60, versus the vehicle (p<0.0001) — meeting the main goal of the study.  Each secondary endpoint also emerged in favor of A-101, the company said.

Charles Nichols, LSU School of Medicine

Could psy­che­delics tack­le the obe­si­ty cri­sis? A long­time re­searcher in the field says his lat­est mouse study sug­gests po­ten­tial

Psychedelics have experienced a renaissance in recent years amid a torrent of preclinical and clinical research suggesting it might provide a path to treat mood disorders conventional remedies have only scraped at. Now a preclinical trial from a young biotech suggests at least one psychedelic compound has effects beyond the mind, and — if you believe the still very, very early hype — could provide the first single remedy for some of the main complications of obesity.

It’s fi­nal­ly over: Bio­gen, Ei­sai scrap big Alzheimer’s PhI­I­Is af­ter a pre­dictable BACE cat­a­stro­phe rais­es safe­ty fears

Months after analysts and investors called on Biogen and Eisai to scrap their BACE drug for Alzheimer’s and move on in the wake of a string of late-stage failures and rising safety fears, the partners have called it quits. And they said they were dropping the drug — elenbecestat — after the independent monitoring board raised concerns about…safety.

We don’t know exactly what researchers found in this latest catastrophe, but the companies noted in their release that investigators had determined that the drug was flunking the risk/benefit analysis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,600+ biopharma pros reading Endpoints daily — and it's free.

Ac­celeron drops a de­vel­op­ment pro­gram as #2 drug fails to spark func­tion­al ben­e­fits in pa­tients with a rare neu­ro­mus­cu­lar ail­ment

Acceleron is scrapping a muscular dystrophy development program underway for its number 2 drug in the pipeline after pouring over some failed mid-stage secondary data.

Gone is the ACE-083 project in patients with facioscapulohumeral muscular dystrophy. Their drug hit the primary endpoint on building muscle but flopped on key secondaries for functional improvements in patients, which execs felt was vital to the drug’s success.